$ACRX I really wish the market cared about formulary wins and REMS, but they don’t. We need revenue... a lot of revenue. $2.3 million for 2019 Q4 will not cut it especially when now all we have is $66 million on hand. I’ve been long here, and will remain long, but either a huge jump in revenue has to come soon or they will do an offering
  • 3
  • 7